MedPath

Lumigan Versus Cosopt

Phase 4
Completed
Conditions
Open-Angle Glaucoma
Registration Number
NCT00273455
Lead Sponsor
Pharmaceutical Research Network
Brief Summary

To compare the intraocular pressure effect and safety of the dorzolamide/timolol fixed combination given twice daily versus bimatoprost given once every evening in patients with open-angle glaucoma in patients insufficiently controlled on latanoprost monotherapy

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
34
Inclusion Criteria
  • adults with a diagnosis of bilateral open-angle glaucoma including: primary, pigment dispersion or exfoliation in both eyes
  • on no therapy the intraocular pressure should be 22-29 mm Hg inclusive at the 8:00 AM measurement
  • visual acuity should be 20/200 or better in each eye
Exclusion Criteria
  • historical failure to respond to topical beta-blockers in a clinically meaningful manner
  • any contraindication to study medications
  • any anticipated change, or modification in the 6 weeks prior to Visit 1, in systemic hypertensive therapy during the trial

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (3)

Houston Eye Associates

🇺🇸

Houston, Texas, United States

Taustine Eye Center

🇺🇸

Louisville, Kentucky, United States

Glaucoma Consultants & Center for Eye Research, PA

🇺🇸

Mt. Pleasant, South Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath